Novavax, Inc. (LON:0A3S)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.17B +45.4% |
| Revenue (ttm) | 451.61M -52.5% |
| Net Income | -66.52M |
| EPS | -0.41 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,388 |
| Average Volume | 124,146 |
| Open | 9.45 |
| Previous Close | 9.55 |
| Day's Range | 9.18 - 9.91 |
| 52-Week Range | 5.87 - 11.97 |
| Beta | 2.37 |
| RSI | 56.49 |
| Earnings Date | May 6, 2026 |
About Novavax
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in ... [Read more]
News
Novavax Transcript: Bank of America Global Healthcare Conference 2026
A major strategic pivot has transformed the business into a technology platform focused on Matrix-M partnerships, generating significant interest and deals with leading pharma companies. The company expects substantial milestone and royalty revenues, a leaner cost structure, and non-GAAP profitability as early as 2028, with a robust pipeline and ongoing R&D supporting future growth.
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Novavax to Participate in BofA Securities 2026 Health Care Conference
GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.
Novavax reports Q1 EPS (6c), consensus (23c)
Reports Q1 revenue $140M, consensus $80.99M. “Novavax (NVAX) continued to make significant progress executing our corporate strategy, which is comprised of partnering our technology, capital-efficient...
Novavax price target raised to $9 from $8 at TD Cowen
TD Cowen raised the firm’s price target on Novavax (NVAX) to $9 from $8 and keeps a Hold rating on the shares. The firm updated its model following the Sanofi-led…
Novavax Earnings Call Transcript: Q1 2026
Q1 2026 saw a sharp revenue drop due to prior-year non-cash items, but partner-related revenues more than doubled and costs fell 23%. The company expanded partnerships, prioritized its C. diff vaccine, and reiterated 2026 guidance, projecting a cash runway into 2028.
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M ® in two infectious disease areas In April, Novavax sig...
Novavax beats first-quarter revenue estimates on vaccine deals strength
Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine supply and licensing deals helped offset pressure from sagging demand.
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m.
Novavax price target raised to $18 from $16 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Novavax (NVAX) to $18 from $16 and keeps a Buy rating on the shares. Activist pressure on governance and…
Shah Capital intends to vote against Novavax's board nominees, executive compensation
Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive compensation package at Novavax's upcoming annual meeting, renewing pressure for changes at t...
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with...
Novavax call volume above normal and directionally bullish
Bullish option flow detected in Novavax (NVAX) with 13,093 calls trading, 3x expected, and implied vol increasing over 6 points to 81.79%. Apr-26 12 calls and Jan-27 10 calls are…
Novavax Transcript: Leerink Global Healthcare Conference 2026
The company has pivoted to a partnership-driven model, leveraging its Matrix-M technology to secure major deals with Sanofi and Pfizer, and is advancing a robust R&D pipeline targeting vaccines and immunotherapies. Financial discipline and strong IP position support a path to profitability by 2028.
Novavax Transcript: TD Cowen 46th Annual Health Care Conference
The company has pivoted to a platform and partnership-driven strategy, highlighted by major deals with Sanofi and Pfizer, expansion of its Matrix-M adjuvant platform, and a robust early-stage pipeline. Financially, it targets profitability by 2028, supported by a strong cash runway and cost reductions.
Novavax price target raised to $8 from $7 at BofA
BofA raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps an Underperform rating on the shares. The firm updated its model with a refreshed COVID…
Novavax price target raised to $7 from $6 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Novavax (NVAX) to $7 from $6 and keeps a Sell rating on the shares.
Novavax price target raised to $16 from $11 at H.C. Wainwright
H.C. Wainwright analyst Sean Lee raised the firm’s price target on Novavax (NVAX) to $16 from $11 and keeps a Buy rating on the shares. The firm says the company’s…
Novavax to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: TD Cowen 46 th Annual Health Car...
Here’s Why Novavax Stock (NVAX) Hit a New 52-Week High on Thursday
Novavax ($NVAX) stock surged over 23% and hit a new 52-week high on Thursday. Investors reacted to strong fourth-quarter results, growing confidence in its vaccine platform, and several major partners...
Novavax Earnings Call Transcript: Q4 2025
Revenue grew 65% year-over-year to $1.1B in 2025, driven by partnerships and cost reductions. Cash runway extends into 2028, with 2026 revenue guidance of $230–$270M and further expense cuts planned. Matrix-M technology and new deals with Pfizer and Sanofi underpin future growth.
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals
Novavax raised its adjusted revenue forecast for 2026 on Thursday, as it expects milestone payments from vaccine supply and licensing deals to offset pressure from sagging demand.
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmace...
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 ...
Novavax Announces Entering into a License Agreement with Pfizer
Non-exclusive license allows for development by Pfizer to utilize Matrix-M ® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the potential fo...